The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in ...

Investigators at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have demonstrated that in the ...

On the tail of rumors that Merck & Co. Inc. and others holding stakes in Personalis Inc. might take over the firm, Chicago-based Tempus AI Inc. ended speculation by disclosing its plan to buy the ...

Rinascera Therapeutics Inc. has secured enough initial funding to acquire two drugs for rare genetic skin diseases, despite ...

Immix Biopharma Inc.’s shares (NASDAQ:IMMX) sank 14% to $8.80 on July 20 after investors learned that a man named Richard Graydon, who served as its chief medical officer, was in fact a 20-year ...

AMT Medical BV reported positive one-year data from a study looking at its ELANA device, a sutureless coronary bypass technology designed to simplify one of the most technically demanding steps in ...

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Cellution, Dimerix, Elutia, IPG, Jasper, Kira, Lumibird, Medtronic, Mission, Red Light Holland, SPR.

U.K. biotech has recorded the strongest quarter for venture capital raised in five years, with companies attracting £2.05 billion (US$3.36 billion) in the second quarter (Q2) of 2026. While that ...

Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In preclinical models of HER2 and EGFR co ...

*For more details about COVID-19 therapeutics and vaccines, diagnostic products and clinical trial delays, go to BioWorld Snapshots.

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in ...

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have reported new dopamine D1 and/or D5 receptor partial agonists. As such, they are reported to be useful for the ...